Abstract: A prospective, comparative study was done in the
Introduction:-"Spring is in the air at last!"
Most of us look forward to the end of the cold dark winter months and all the delights of the spring season, but for the patients of allergic rhinitis, it is the worst time of the year.
Rhinitis is defined as inflammation of the nasal mucosa and is characterized by symptoms of congestion, rhinorrhoea, itching of the nose, postnasal drip, and sneezing. Rhinitis can be divided broadly into following major categories:| Allergic, Nonallergic and Infective. 1, 2 Allergic rhinitis, which is best, defined as that adverse pathophysiological response of the nose and adjacent organs that result from the interaction of allergen with antibody in a host sensitized by previous exposure to that allergen. 3, 4 Allergic rhinitis is the most common atopic disorder affecting large number of adults worldwide. 2, 4, 5, 6 Estimates of the prevalence of the allergic rhinitis in different countries vary from 0.5% to 28.0%. 3, 7 The high prevalence of allergic rhinitis and its effect on quality of life have led to its being classified as a major chronic respiratory disease.
Common manifestations of the allergic rhinitis include paroxysmal sneezing, nasal blockage, and watery nasal discharge. In clinical examination there may be pale or bluish boggy inferior turbinates with watery nasal discharge. The conjunctivae may be hyperaemic and oedematous.
Group B:
Patients between age group of 6-11 years received one puff of \/Azelastine 0.14 mg in each nostril twice daily and patients aged 12 years and above received two puffs of Azelastine in each nostril twice daily. 9, 10  During the treatment and follow up the efficacy was assessed by using TNSS scale and tolerability by MTTES scale weekly for a period of 6 weeks scores for the following symptoms of TNSSandMTTES were recorded from 0 to 3.
TOTAL NASAL SYMPTOM SCORE (TNSS):
Under TNSS scale following symptoms : a. Rhinorrhea, Sneezing, Itchy nose, Nasal congestion were assessed and scores were recorded from 0-3 (absent -severe 4, 10, 11, 12, 13 Scores Definitions Symptoms For TNSS 0 Absent Symptom is not present •R1hinorrhea.
•Sneezing.
•Itchy nose. Nasal congestion. • Dislikeness for meals.
• Day time sleeping.
• Additional medication. The primary efficacy and tolerability end points were change from baseline in the total nasal symptom score (TNSS) and modified treatment tolerability evaluation score (MTTES) respectively. The data was pooled and observations were recorded. I
The effect of Montelukast and Azelastine on Absolute Eosinophil count in blood was recorded at 0 and 6 weeks in both the groups.
Absolute Eosinophil count
 0 weeks : Before the start of the therapy (first Visit)  6 week : After the completion of therapy (last Visit) SAMPLE SIZE:
 50 patients were included in each group according to inclusion and exclusion criteria. 
STATISTICAL ANALYSIS:
The data was collected and subjected to statistical analyses by applying "Z" test of significance and based on these results the conclusions were drawn By applying Z test of difference between two means there is highly significant difference between mean baseline Sneezing scores of patients of allergic rhinitis of Group A (Montelukast treated) and Group B (Azelastine treated) from 1-6 week (pO.Ol) Graph 3b By applying 'Z' test of difference between two means there is highly significant difference between mean baseline Itchy nose scores of patients of allergic rhinitis of Group A (Montelukast treated) and Group B (Azelastine treated) from 1-6 week (pO.Ol) Graph 3c By applying 'Z' test of difference between two means there is highly significant difference between mean TNSS of patients of allergic rhinitis of Group A (Montelukast treated) and Group B (Azelastine treated) from 1-6 week(p<0.01) Graph 3e: By applying Z test of difference between two sample means there is no significant difference between mean values of absolute eosinophil count at 0 week in group A and group B (i.e.p>0.05) and there is highly significant difference between mean values of absolute eosinophil count at 6 week in group A and group B (i.e. p <0.01) Graph no 4 Comparison of mean baseline Individual tolerabilityscores of patients of Allergic Rhinitis Table 6a :
OBSERVATIONS

Comparison of mean Absolute Eosinophil count at 0 and 6 weeks of Group A (Montelukast treated) and Group B (Azelastine treated) patients of Allergic
The comparison of mean baseline tolerability Vomiting scores of patients of allergic rhinitis of Group A (Montelukast treated) and Group B (Azelastine treated) from 0-6 week:
W E E KS Montelukast (n=50) Mean ± SD Azelastine (n=50) Mean ± SD 
Graph 6a
The comparison of mean baseline tolerability vomiting scores of patients of allergic rhinitis of Group A (Montelukast treated) and Group B (Azelastine treated) from 0-6 week By applying 'Z' test of difference between two means there is Significant difference between mean tolerability Day time sleeping scores of patients of allergic rhinitis of Group A (Montelukast treated) and Group B (Azelastine treated) from 2-5 week (p<0.05). There is no significant difference in mean tolerabilityDay time sleeping scores at 0, 1 and 6 weeks. 
Graph 6c
